Absorption and Systemic Study of AN2690 in Patients With Moderate to Severe Onychomycosis (ADME II)
NCT00679601
ABOUT THIS STUDY
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
1-800-718-1021
Adult Trials: 18+ Years
- Male or female ≥18 and ≤65
- BMI between 18.5 and 35 inclusive
- Moderate to severe onychomycosis involving ≥80% of both great toenails, as determined by visual inspection after the nail has been trimmed
- Combined thickness of the nail plate and nail bed of each great toenail is >3mm
- At least 6 additional toenails with a clinical diagnosis of onychomycosis
- If a female of childbearing potential, must be using of a highly effective method of birth control or abstinence and be willing to remain on that same method of birth control throughout the study
- Capable of understanding and signing the informed consent, and willing to comply with all requirements of the study
- History of allergy to any of the study drug or any components in the test product(s)
or history of hypersensitivity or allergic reactions to any of the study preparations
as described in the Investigator's Brochure
- Clinically significant laboratory abnormalities that would interfere with the conduct
or interpretation of the study or jeopardize his/her safety
- Diabetes mellitus requiring treatment other than diet and exercise
- Willing to refrain from the use of nail cosmetics such as clear and or colored nail
lacquers from the screening visit until the end of the study
- Nursing, pregnant or planning to become pregnant during the study
- Failure to complete the specified washout period(s) for the following topical:
1. Topical antifungal applied to the feet (does not include antifungals for
treatment of T. pedis during the study): 4 weeks
2. Anti-inflammatories, corticosteroids, topical immunomodulators: 2 weeks
- Failure to complete the specified washout period(s) for the following systemic
medications:
1. Corticosteroids (including intramuscular injections): 2 weeks
2. Antifungals for treatment of onychomycosis or any systemic antifungal with known
activity against dermatophyte: 24 weeks
3. Systemic immunomodulators: 4 weeks
- Received treatment of any type for cancer within the last 6 months
- History of any significant internal disease
- Nail or anatomic abnormalities of the toe, e.g., genetic nail disorders, primentary
disorders, onychogryphosis, trauma to the nail(s) to be treated
- AIDS or AIDS related complex
- History of street drug or alcohol abuse
- Donated or lost blood, or participated in a clinical study which involved the
withdrawal of a large volume of blood (480 mL or more), during the six-week period
preceding study initiation
- Donated plasma during the two week period preceding study initiation
- Participated in any other trial of an investigational drug or device within 30 days
prior to enrollment or participation in a research study concurrent with this study
- Prior enrollment in a study using the study drug, AN2690
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- Bryan, Texas
- Bryan, Texas
- Chihuahua,
- Guadalajara,
- Guadalajara,
- Mexico City,
- Mexico City,
- Mexico City,
- Monterrey,
- Monterrey,
- Toluca,
- Birmingham, Alabama
- San Francisco, California
- Albuquerque, New Mexico
- New York, New York
- Austin, Texas
- Bryan, Texas
- San Antonio, Texas
| Descriptive Information | ||||
|---|---|---|---|---|
| Brief Title ICMJE | Absorption and Systemic Study of AN2690 in Patients With Moderate to Severe Onychomycosis (ADME II) | |||
| Official Title ICMJE | An Open-label, Multiple-dose Study Of The Absorption And Systemic Pharmacokinetics Of An2690 Applied As A 7.5% Solution To All Toenails Of Adult Patients With Moderate To Severe Onychomycosis | |||
| Brief Summary | The purpose of the study is to determine the absorption and systemic pharmacokinetics of AN2690 following daily application to all ten (10) toenails for 28 days. | |||
| Detailed Description | A single center, open-label, multiple-dose study design will be used. Planned enrollment is 20 subjects to complete 15. Subjects must have a clinical diagnosis of onychomycosis of each great toenail and a clinical diagnosis of onychomycosis of six of the remaining toenails. | |||
| Study Type ICMJE | Interventional | |||
| Study Phase ICMJE | Phase 2 | |||
| Study Design ICMJE | Masking: None (Open Label) Primary Purpose: Treatment | |||
| Condition ICMJE | Onychomycosis | |||
| Intervention ICMJE | Drug: AN2690
AN2690 7.5% Solution, once daily for 28 days | |||
| Study Arms ICMJE | Not Provided | |||
| Publications * | Not Provided | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
| Recruitment Information | ||||
| Recruitment Status ICMJE | Completed | |||
| Actual Enrollment ICMJE | 20 | |||
| Original Actual Enrollment ICMJE | Same as current | |||
| Actual Study Completion Date ICMJE | May 31, 2007 | |||
| Actual Primary Completion Date | May 31, 2007 (Final data collection date for primary outcome measure) | |||
| Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
| |||
| Sex/Gender ICMJE |
| |||
| Ages ICMJE | 18 Years to 65 Years (Adult, Older Adult) | |||
| Accepts Healthy Volunteers ICMJE | No | |||
| Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | |||
| Listed Location Countries ICMJE | United States | |||
| Removed Location Countries | ||||
| Administrative Information | ||||
| NCT Number ICMJE | NCT00679601 | |||
| Other Study ID Numbers ICMJE | AN2690-ONYC-205 C3371014 ( Other Identifier: Alias Study Number ) | |||
| Has Data Monitoring Committee | No | |||
| U.S. FDA-regulated Product | Not Provided | |||
| IPD Sharing Statement ICMJE | Not Provided | |||
| Responsible Party | Pfizer | |||
| Study Sponsor ICMJE | Pfizer | |||
| Collaborators ICMJE | Not Provided | |||
| Investigators ICMJE |
| |||
| PRS Account | Pfizer | |||
| Verification Date | February 2018 | |||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP | ||||